Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck

This commentary highlights the article by Parikh and colleagues, regarding biweekly therapy with the anti-EGFR monoclonal antibody, cetuximab, for gastrointestinal cancer.

Detalles Bibliográficos
Autor principal: Kasi, Pashtoon Murtaza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074985/
https://www.ncbi.nlm.nih.gov/pubmed/35403691
http://dx.doi.org/10.1093/oncolo/oyac070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074985/
https://www.ncbi.nlm.nih.gov/pubmed/35403691
http://dx.doi.org/10.1093/oncolo/oyac070

Ejemplares similares